ASH 2021 | Genomic profiling of smoldering myeloma identifies high- and low- risk patients
Shankara Anand
• 12 Dec 2021
In this video, Shankara Anand, MS, Broad Institute of MIT & Harvard, Cambridge, MA, discusses genomic profiling of smoldering multiple myeloma (SMM). Mr Anand first describes SMM and the current standard of care, which tends to be a ‘wait and watch’ approach. Following this, Mr Anand emphasizes the benefits of identifying patients who are high-risk and treating them before their disease progresses to multiple myeloma (MM). To conclude, Mr Anand briefly discusses a study which conducted comprehensive genomic profiling on patients with SMM, and how this helped to more accurately identify high- and low- risk patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
